Clinical Outcomes of Deep Brain Stimulator (DBS) Electrodes Placed Using Intraoperative Computed Tomography (CT) and Frameless Stereotaxis

Parkinson's Disease Clinical Trial

Official title:

Clinical Outcomes of Deep Brain Stimulator Electrodes Placed Using Intraoperative Computed Tomography and Frameless Stereotaxis Versus Microelectrode Recording and Frame-based Stereotaxis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01703598
• Other study ID #: IRB00007508
• Status: Completed
• Phase: N/A
• Start date: September 2011
• Est. completion date: March 2017

Study information

• Verified date: July 2019
• Source: Oregon Health and Science University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether performing deep brain stimulation surgery for Parkinson's disease using intraoperative imaging and frameless stereotaxis is noninferior to using frame-based stereotaxy and microelectrode recording.

Description:

Background: Frame-based stereotaxis and microelectrode recording (MER) with mapping of target structures has been the gold standard for deep brain stimulator (DBS) implantation. Though supported by historical considerations, no Class I or II evidence exists that MER adds significant value to the DBS implant procedure. With the advent of advanced magnetic resonance imaging (MRI) and computed tomography (CT) imaging, particularly intra-operative imaging, the argument for the continued use of MER during DBS implantation has been substantially weakened. One rationale for pursuing CT-guided intraoperative imaging is due to presumed increase in patient comfort with this method. DBS implantation with MER requires that the patient remain awake during the entire procedure. , MER with frame-based stereotaxis requires the patient to keep their head in a fixed position for a prolonged period of time during which time they remain awake, causing significant patient discomfort. Furthermore, Parkinson's disease patients must withhold their PD meds for a minimum of 12 hours prior to the procedure adding a sometimes significant degree of discomfort and anxiety to the procedure.

Objective: The goal of this study is to compare the clinical outcomes of DBS electrodes placed using intraoperative CT and frameless stereotaxis with those placed using MER and frame-based stereotaxis.

Design: The proposed study will be a prospective non-interventional data collection study.

Setting and Subjects: Subjects for this study will be idiopathic Parkinson's disease patients identified from the Oregon Health & Science University movement disorder clinic as candidates for deep brain stimulation therapy. Enrollment will continue until fifty subjects have been implanted with electrodes using frameless stereotaxis and intraoperative CT. Data regarding quality of life, motor control, and amount of time during the day without levodopa side effects will be collected pre-operatively and post-operatively. This data will be compared to historical controls who have been implanted with DBS electrodes using MER and frame-based stereotaxis. All surgical procedures will involve only Federal Drug Administration (FDA) approved stereotactic equipment, used in the manner for which they have been approved. All clinic procedures are standard of care for movement disorders patients in the deep brain stimulation program.

Intervention: This study will be a non-interventional data collection study.

Measurements: Data regarding patient age, diagnosis, intracranial target, complications, Unified Parkinson's Disease Rating Scale UPDRS Parts 3 (motor examination) and 4 (drug side effects), Parkinson's Disease Quality of life PDQ-39, 3 day motor diary, 3 month falls diary, neuropsychiatric evaluation and days in hospital following surgery will be collected.

Analysis: The patients will be examined prior to DBS placement both on and off dopaminergic medications. They will then be examined 3 months and 6 months following DBS placement both on and off drug with stimulator on after programming parameters have been optimized. The following measures will be performed:

• Change in UPDRS Parts 3 and 4

• Change in PDQ-39

• Change in amount of time patient is experiencing Parkinson's disease symptoms and/or side effects of treatment.

• Change in number of falls

• Change in neuropsychiatric evaluation, including:

• Beck Depression Inventory-II (BDI-II)

• Mattis Dementia Rating Scale-Second Edition (DRS-2)

• Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

• Symptom Checklist-90-Revised (SCL-90-R)

• Wechsler Abbreviated Scale of Intelligence (WASI) We will also compare the number of days spent in hospital following surgery. Adverse events related to the surgery will be captured.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: March 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Idiopathic Parkinson's disease patients identified by OHSU movement disorders neurologists as deep brain stimulation surgical candidates

Exclusion Criteria:

• Subjects who have already undergone implantation of DBS electrodes 2.Age < - - 18 years

• Surgical target site other than subthalamic nucleus or globus pallidus pars interna

• Subjects who choose to undergo MER and frame-based stereotaxis for the placement of electrodes.

• Patients who will receive follow up neurology care and DBS programming at centers other than OHSU.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Device:
• Deep Brain Stimulation
Placement of Deep Brain Stimulation electrodes

Procedure:
• DBS surgery
Placement of DBS electrodes

Locations

Country	Name	City	State
United States	Oregon Health & Science University	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Motor OFF Ldopa UPDRS	Change in motor UPDRS in OFF Levodopa state. The range of this outcome is from 0 to 108, a higher number indicated a worse clinical state.; The number represents units on this scale.	Baseline and 6 months